These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 39043719)
21. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems. Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188 [TBL] [Abstract][Full Text] [Related]
22. [Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum β-Lactamase-producing Escherichia coli]. Sugawara T; Murakami N; Uetake N; Hiraki K Yakugaku Zasshi; 2015; 135(6):829-33. PubMed ID: 26028418 [TBL] [Abstract][Full Text] [Related]
23. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. Cheong HS; Kang CI; Kwon KT; Heo ST; Wi YM; Kim ES; Lee JS; Ko KS; Chung DR; Lee NY; Song JH; Peck KR J Antimicrob Chemother; 2007 Dec; 60(6):1355-60. PubMed ID: 17923453 [TBL] [Abstract][Full Text] [Related]
24. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia. Van Aken S; Lund N; Ahl J; Odenholt I; Tham J Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648 [TBL] [Abstract][Full Text] [Related]
25. Do Weekly Surveillance Cultures Contribute to Antibiotic Stewardship and Correlate with Outcome of HSCT in Children? A Multicenter Real-World Experience of 5 Years from the Indian Subcontinent. Dhanya R; Agarwal RK; Ramprakash S; Trivedi D; Shah V; Bhat N; Reddy M; Elizabeth S; Batool A; Khalid S; Faulkner L Transplant Cell Ther; 2022 Mar; 28(3):170.e1-170.e7. PubMed ID: 34936930 [TBL] [Abstract][Full Text] [Related]
26. Association of Empiric Antibiotic Regimen Discordance With 30-Day Mortality in Neonatal and Pediatric Bloodstream Infection-A Global Retrospective Cohort Study. Cook A; Hsia Y; Russell N; Sharland M; Cheung K; Grimwood K; Cross J; Cotrim da Cunha D; Magalhães GR; Renk H; Hindocha A; McMaster P; Okomo U; Darboe S; Alvarez-Uria G; Jinka DR; Murki S; Kandraju H; Dharmapalan D; Esposito S; Bianchini S; Fukuoka K; Aizawa Y; Jimenez-Juarez RN; Ojeda-Diezbarroso K; Pirš M; Rožič M; Anugulruengkitt S; Jantarabenjakul W; Cheng CL; Jian BX; Spyridakis E; Zaoutis T; Bielicki J Pediatr Infect Dis J; 2021 Feb; 40(2):137-143. PubMed ID: 33395208 [TBL] [Abstract][Full Text] [Related]
27. E. coli bacteraemia and antimicrobial resistance following antimicrobial prescribing for urinary tract infection in the community. McCowan C; Bakhshi A; McConnachie A; Malcolm W; Barry SJ; Santiago VH; Leanord A BMC Infect Dis; 2022 Oct; 22(1):805. PubMed ID: 36307776 [TBL] [Abstract][Full Text] [Related]
28. Bacterial clonal diagnostics as a tool for evidence-based empiric antibiotic selection. Tchesnokova V; Avagyan H; Rechkina E; Chan D; Muradova M; Haile HG; Radey M; Weissman S; Riddell K; Scholes D; Johnson JR; Sokurenko EV PLoS One; 2017; 12(3):e0174132. PubMed ID: 28350870 [TBL] [Abstract][Full Text] [Related]
29. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Kang CI; Chung DR; Ko KS; Peck KR; Song JH; Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875 [TBL] [Abstract][Full Text] [Related]
30. Bacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes. Zhang Q; Zhang W; Li Z; Bai C; Li D; Zheng S; Zhang P; Zhang S Diagn Microbiol Infect Dis; 2017 Jul; 88(3):247-251. PubMed ID: 28434898 [TBL] [Abstract][Full Text] [Related]
32. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669 [TBL] [Abstract][Full Text] [Related]
33. Factors that impact on the burden of Escherichia coli bacteraemia: multivariable regression analysis of 2011-2015 data from West London. Blandy O; Honeyford K; Gharbi M; Thomas A; Ramzan F; Ellington MJ; Hope R; Holmes AH; Johnson AP; Aylin P; Woodford N; Sriskandan S J Hosp Infect; 2019 Feb; 101(2):120-128. PubMed ID: 30403958 [TBL] [Abstract][Full Text] [Related]
34. Acute uncomplicated UTI and E. coli resistance: implications for first-line empirical antibiotic therapy. Perfetto EM; Keating K; Merchant S; Nichols BR J Manag Care Pharm; 2004; 10(1):17-25. PubMed ID: 14720102 [TBL] [Abstract][Full Text] [Related]
35. Antimicrobial resistance associations with national primary care antibiotic stewardship policy: Primary care-based, multilevel analytic study. Hammond A; Stuijfzand B; Avison MB; Hay AD PLoS One; 2020; 15(5):e0232903. PubMed ID: 32407346 [TBL] [Abstract][Full Text] [Related]
36. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828 [TBL] [Abstract][Full Text] [Related]
37. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653 [TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910 [TBL] [Abstract][Full Text] [Related]
39. Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005-2014. Stapleton PJ; Lundon DJ; McWade R; Scanlon N; Hannan MM; O'Kelly F; Lynch M Ir J Med Sci; 2017 Aug; 186(3):733-741. PubMed ID: 28054236 [TBL] [Abstract][Full Text] [Related]
40. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases. Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]